Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
CIPLA
Mr. Achin Gupta · Mumbai, India · 31,369 employees
₹1,474.30
▲+2.06%CIPLA.NS is experiencing a moderate upward momentum due to its improving operational efficiency, diversified product portfolio, and steady revenue growth.
Exchange
NSI
Currency
INR
Day range
₹1,442.00 – ₹1,491.20
52-week range
₹1,165.70 – ₹1,673.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis80% confidence
The valuation appears slightly rich at the current levels, trading in the upper third of its 1-year range, but the company's consistent earnings growth and improving profitability justify a premium.
11.9% below the 1-year high · trend up
Hedge-fund memo
Today
The stock has rallied 2.06% today, supported by overall market positivity, and has reached a 14-period high. However, volumes are lower than the 1-year average.
This week
The stock has traded within a relatively narrow range between the 1442 and 1491.2 levels, with occasional touches on both the upper and lower bounds.
This month
CIPLA.NS has been trading sideways, oscillating between the 52-week high of 1673 and the low of 1165.7.
Bull thesis
Bear thesis
News & sentiment
Bullish
24 headlines · 21 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 4 recent quarters (EPS actual vs. consensus).
9.76 vs 10.423
-6.36% surprise
6.86 vs 9.67141
-29.07% surprise
10.9379 vs 15.55312
-29.67% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| CIPLA | 1.19T | 35.31 | — | 12.55% | 3.50% |
| DRREDDY | 951.54B | 28.74 | 8.84% | 4.25% | -5.60% |
| SUNPHARMA | 4.77T | 41.59 | 14.72% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Rising raw material costs
Mitigation: Diversification of product portfolio and sourcing strategies can help mitigate these risks
Business intelligence
Competitive moat
CIPLA's broad product portfolio, strategic partnerships, and geographical diversification provide a sustainable competitive advantage in the generic and specialty pharmaceutical market.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Revenue guidance and profit forecast
Thesis builder
Bull case
Operational efficiency improvements and geographical expansion can drive significant top-line growth over the next 2-3 years, with a potential CAGR of 10-12%.
Base case
The company is likely to maintain its market share and profitability over the next 1-2 years, with a moderate growth rate of 5-6%.
Bear case
A material decline in generic medicine prices or increasing competition from established players can erode the company's profit margins and growth prospects.
Time horizon
Short-term focus on stabilizing the revenue growth and improving profitability, medium-term emphasis on expanding into new markets and products.
Est. CAGR
8-12%
Entry (qual.)
Investors can consider entering the stock at the current levels, with a relatively short-term perspective.
Exit (qual.)
A 25-30% upside potential exists over the next 1-2 years, making it an attractive exit point.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how CIPLA fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain CIPLA for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
The company's strong financial performance and improving profitability make it an attractive investment opportunity, but investors should monitor its exposure to macroeconomic risks.
BioSpectrum India·8h ago·expands public health screening reach
The Indian Practitioner·10h ago·nationwide hepatitis screening launch
expresshealthcare.in·11h ago·hepatitis campaign on awareness day
TradingView·12h ago·FDA approval plus analyst upside
goodreturns.in·13h ago·FDA nod but share reaction weak
ET Pharma·14h ago·FDA approval for Advair generic
NDTV Profit·18h ago·analysts see bigger opportunity ahead
NDTV Profit·19h ago·mentioned among many stock picks
LinkedIn·1d ago·FDA win but years behind schedule
The Hindu·1d ago·FDA approval for respiratory drug
Pharmabiz.com·1d ago·hepatitis mission scale-up positive
insights.citeline.com·1d ago·joins generic Advair club with FDA
Express Pharma·1d ago·FDA nod for Advair Diskus generic
Upstox·1d ago·irrelevant share price tag only
scanx.trade·2d ago·record quarterly revenue reported
Everything Experiential·2d ago·D2C wellness push at festival
afaqs!·2d ago·targeting devotees for D2C push
The Economic Times·2d ago·strong pipeline offset by US drag
The Morning Context·3d ago·conservative approach is hurting growth
scanx.trade·3d ago·record revenue tempered by margin dip
Medical Dialogues·3d ago·routine corporate disclosure revision
simplywall.st·3d ago·earnings missed analyst estimates
scanx.trade·4d ago·new global CFO appointment
Yahoo Finance·4d ago·strong start with record revenue
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
16.72 vs 16.34085
2.32% surprise
| 19.23% |
| 12.80% |
| LUPIN | 1.12T | 21.02 | 26.91% | 24.22% | 31.90% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,442.00
Resistance (day/52w high)
₹1,491.20
Volume
21,92,190
Trend
up
RSI (14)
58
MACD
bullish
MA cross
golden
50-day MA
₹1,414.65
200-day MA
₹1,397.89
vs 200-DMA
5.5%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 80%